EPO and cancer: Based on the paper by Dr. Elliott and on the testimony of Dr. Lodish, who was also the legal advocate for Amgen in patent disputes [76,77,78], the FDA did not take any decision on an eventual restriction of the use of EPO in cancer patients for a long time.